MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Biotechnology

Healthcare
$53.42 -1.54%

-$0.64 today

Market cap
$2.65B
Beta
0.75
P/E (TTM)
-22.0
EPS (TTM)
-$1.86
52W Low $9.43High $45.85

Volume 0.73M

Average 0.65M

MBX Other Financing Activities

Financing cash flows not reported separately.

MBX Biosciences, Inc. Common StockNASDAQ: MBX

Other Financing Activities · Q3 FY2026 · quarter ended Sep 2026

Other financing activities turns negative

Q3 FY2026 other financing activities was -$31K, compared with $0 a year earlier. Trailing-twelve-month other financing activities was $85.21M.

Context

  • Other financing activities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly other financing activities holds near -$31K or moves back toward the trailing-twelve-month quarterly average of $21.3M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$31K-100.0% QoQ
Last fiscal yearDec 2025
$0+100.0% YoY
LTMSep 2026
$85.21M+26159.0% YoY
Other Financing Activities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Financing Activities history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
+100.0%

Other Financing Activities vs competitors

How MBX compares with its peers on the latest reported figures

  • Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26159.0% is the highest of 8, against a peer median of +38.7%.
MBX Competitors
Other Financing Activities for MBX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRAKailera Therapeutics, Inc.FY2025$499.19M USD———
VKTXViking Therapeutics, Inc.LTM Jun 2026$108.15M USD+2970.6%+80.9%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$85.21M USD+26159.0%——
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$17.56M USD+576.3%—6.3%
ASNDAscendis Pharma A/SLTM Sep 2026€12.86M EUR+3.8%—1.1%
ALTAltimmune, Inc.LTM Mar 2026$717K USD+38.7%—1991.7%
BMEABiomea Fusion, Inc.LTM Mar 2026$3K USD-100.2%——
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$0 USD-100.0%—0.0%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$0 USD+100.0%——
Peer median (excluding MBX) —+38.7%+80.9%3.7%

Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(26.14M)(32.56M)(61.92M)(86.97M)
Depreciation & Amortization56K157K244K248K
Deferred Income Tax0000
Stock-Based Compensation306K2.04M5.22M8.68M
Change in Working Capital1.29M(735K)4.6M1.58M
Accounts Receivables0000
Inventory0000
Accounts Payables671K412K3.93M(2.46M)
Other Working Capital619K(1.15M)670K4.03M
Other Non-Cash Items1.36M(880K)(2.82M)(3.48M)
Operating Cash Flow(23.12M)(31.98M)(54.68M)(79.95M)
Capital Expenditures(441K)(129K)(874K)(1.93M)
Acquisitions (Net)0000
Purchases of Investments(20.22M)(63.8M)(239.47M)(358.15M)
Sales of Investments9.25M33M79.75M267.87M
Other Investing Activities0008.5M
Investing Cash Flow(11.41M)(30.93M)(160.6M)(83.71M)
Debt Repayment10M000
Common Stock Issued30K739K174.54M189.59M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities(428K)(30K)(3.94M)0
Financing Cash Flow46.06M69.22M234.1M189.59M
Effect of Forex Changes0000
Net Change in Cash11.53M6.31M18.83M25.94M
Free Cash Flow(23.56M)(32.11M)(55.56M)(81.88M)

MBX Biosciences, Inc. Common Stock

NASDAQ:MBX

Intrinsic Alpha fair value

Locked

Current Price

$53.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.